SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00897455

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Genetic Modifiers of BRCA1/BRCA2-Related Breast Cancer Risk in BRCA1/BRCA2 Mutation Carriers - CIMBA 5

RATIONALE: Studying samples of DNA in the laboratory from women who are BRCA1/BRCA2 mutation carriers may help doctors learn more about cancer and identify biomarkers related to cancer. PURPOSE: This research study is looking at breast cancer risk in women who are BRCA1/BRCA2 mutation carriers.

NCT00897455 brca1 Mutation Carrier brca2 Mutation Carrier Breast Cancer
MeSH:Breast Neoplasms
HPO:Breast carcinoma Neoplasm of the breast

5 Interventions

Name: DNA analysis

Type: Genetic

Name: mutation analysis

Type: Genetic

Name: polymorphism analysis

Type: Genetic

Name: laboratory biomarker analysis

Type: Other

Name: evaluation of cancer risk factors

Type: Procedure


Primary Outcomes

Measure: Identification of potential genetic modifiers of breast cancer risk

There are 3 SNPs

SNPs


1 rs16942

Previously collected DNA samples are analyzed for genetic variants in selected candidate genes (rs16942 in BRCA1, rs2237060 in RAD50, "SNP3", and rs2241193 in IGFBP5).


2 rs2237060

Previously collected DNA samples are analyzed for genetic variants in selected candidate genes (rs16942 in BRCA1, rs2237060 in RAD50, "SNP3", and rs2241193 in IGFBP5).


3 rs2241193

Previously collected DNA samples are analyzed for genetic variants in selected candidate genes (rs16942 in BRCA1, rs2237060 in RAD50, "SNP3", and rs2241193 in IGFBP5).



HPO Nodes


HPO: